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Abstract 
The therapeutic potential of a nucleoside analog, gemcitabine, is severely compromised due to its 
rapid clearance from systemic circulation by enzymatic degradation into inactive metabolite. In 
the present investigation, micelles based on polymer-drug conjugate were developed for 
gemcitabine and investigated for their potential to improve cancer chemotherapy. The tocopherol 
poly(ethylene glycol) succinate 1000 (TPGS)-Gemcitabine prodrug was synthesized via amide 
linkage and characterised by analytical methods, including FT-IR, 
1
H-NMR, and MALDI-TOF. 
The micellar formulation of TPGS-Gemcitabine prodrug was developed by self-assembly 
technique and evaluated for various physicochemical parameters including particle size, 
polydispersity, morphology, critical micelle concentration and release profile. It was shown 
observed that gemcitabine present in TPGS-Gemcitabine micelles were resistant to deamination 
from crude cytidine deaminase. The improved cytotoxicity of the micellar formulation was 
observed by TPGS-Gemcitabine micelles against pancreatic cancer cells. Further, it was 
investigated that unlike native gemcitabine, the nucleoside transporters were not required for 
TPGS-Gem micelles to demonstrate its anticancer potential. These finding revealed that TPGS-
Gemcitabine micelles may serve as a promising platform for gemcitabine in order to improve its 
anticancer efficacy. 
Keywords: gemcitabine, TPGS, prodrug, micelles, pancreatic cancer 
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1. Introduction 
Pancreatic cancer is known as the most lethal malignant disease
1
. Despite the therapeutic 
advances, 80–85% of cases were detected in highly metastasis state, and complicated to treat 
with a median survival of <6 months
2
. The anatomy and biology of pancreatic cancer also 
conspire to elude detection and resist eradication
3
. Gemcitabine is a strong cytidine analog 
approved by FDA for the management of pancreatic cancer and variety of solid tumours 
4
. At 
present, gemcitabine is used as single agent for therapy of advanced pancreatic cancer and is the 
most prescribed anticancer drug worldwide, in spite of growing resistance 
5, 6
. In the recent years, 
several trials demonstrated the efficacy of targeted therapy or combination chemotherapy, 
however, none of them changed the practice of gemcitabine monotherapy
7, 8
. Moreover, the 
clinical efficacy of gemcitabine also compromised by its rapid clearance through enzymatic 
metabolism driven by cytidine deaminase (CDA), which is ubiquitously expressed in the liver 
and blood plasma
9, 10
. The high degree of hydrophilicity of gemcitabine further decreases its 
efficacy by restricting its permeation of the dense vasculature exterior of the tumour. Therefore, 
a high drug dose is required to achieve therapeutic concentration or desired effect, which causes 
serious side effects. 
Many efforts have been employed to advance the efficiency of gemcitabine, including 
nanoparticles
11, 12
, liposomes
13, 14
, micelles
15, 16
, polymer-drug conjugates (Prodrugs)
17, 18
. 
Besides other efforts, gemcitabine prodrugs received a constant recognition for its enhance 
metabolic stability, improved cellular uptake or cytotoxicity and to limit the resistance. Various 
chemically modified prodrugs of gemcitabine were reported either employing hydrophilic 
polymers, includes polyethylene glycol (PEG)
 18
 and poly-glutamic acid (PGA)
 19
 or lipophilic 
agents such as linoleic acid
20
 and squalene
21
. Moreover, amphiphilic polymer-drug conjugates or 
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lipophilic prodrug conjugates are more attractive due to their self-assembling characteristics into 
nano-micelles upon dilution with water. Micelles, based on polymer-drug conjugate (prodrug) is 
an exciting development of polymeric drug delivery systems and have dual benefits arising from 
the polymer-drug conjugate itself as well as the properties gained from micellar formulations. 
Various gemcitabine formulations based on an amphiphilic polymers or lipid-based micelles 
have been reported to possess improved efficacy of gemcitabine. Chitkara et al.
22
 reported 
gemcitabine conjugated poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-
propylenecarbonate) (PEG-PCC) self-assembled micelles improves plasma stability and in-vivo 
efficacy of  gemcitabine against MiaPaCa-2 cells derived xenograft tumour in mice. In another 
study, Daman et al.
15
 compared the in-vitro efficacy of 4-(N)-stearoyl gemcitabine (GemC18) 
loaded PEG-PLGA micelles and 4-(N)-stearoyl gemcitabine self-assembled micelles against 
pancreatic cancer and reported the higher efficacy of self-assembled 4-(N)-stearoyl gemcitabine 
micelles. Recently, Han et al.
23
 demonstrated the high cytotoxicity of gemcitabine conjugated 
PEG-b-[PLA-co-PMAC-graft-(IR820-co-GEM)] self-assembled theranostic micelles in BxPC-3 
cells and higher accumulation in the tumour tissue.  
To extend this concept of self-assembled micelles based on amphiphilic polymer-drug 
conjugate, in the present investigation, we have designed a gemcitabine prodrug in which drug is 
conjugated with such amphiphilic polymer, which possesses additional therapeutic values. D-
alpha-tocopherol polyethylene glycol succinate (TPGS) was used as an amphiphilic polymer to 
synthesize gemcitabine prodrug. TPGS is an amphiphilic derivative of natural vitamin E (α-
tocopherol), synthesized by grafting α-tocopherol with polyethylene glycol oligomer via a 
succinate linker and gained interest in the development of drug delivery systems
24
. TPGS has 
been permitted by FDA as a drug solubiliser, in a variety of formulations and listed as a GRAS 
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(generally referred as safe) supplement, also used as an absorption enhancer and stabiliser
25, 26
. It 
has been reported that TPGS acts as an anticancer agent alone or synergistically with 
chemotherapeutic drugs
27-31
. Recently, Neophytou et al. investigated that the intrinsic anticancer 
activity of TPGS is due to the inhibition of phospho-AKT and the downregulation of the anti-
apoptotic proteins survivin and Bcl-2 
27
. In addition, it has been reported that the inhibition of 
survivin expression in pancreatic cancer could potentiate the activity of gemcitabine 
significantly
32, 33
.  
Previously we have investigated the potential of poly(lactide-co-glycolide)-gemcitabine 
prodrug conjugate in an attempt to improve the efficacy of gemcitabine.
17
 In this work, we 
synthesized TPGS-Gemcitabine (TPGS-Gem) prodrug to protect the drug from enzymatic 
metabolism. The TPGS-Gem prodrug was characterized for self-assembly properties to explore 
their potential as drug delivery carrier for improved efficacy of gemcitabine.  
2. Experimental 
2.1 Materials 
Gemcitabine was purchased from Fluorochem (UK). Tocopherol poly(ethylene glycol) succinate 
1000, dimethylamino pyridine, succinic anhydride, N-hydroxysuccinimide (NHS), N, N’-di 
cyclohexyl carbodiimide (DCC), dry dichloromethane, diethyl ether and ethanol were purchased 
from Sigma-Aldrich (UK). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human 
cytidine deaminase (specific activity 3.5unit/mg) was obtained from ProSpec (USA). The human 
pancreatic cancer cells (BxPC-3) were procured from European Collection of Cell Cultures 
(ECACC, LGC Standards, UK) and grown in complete growth medium, Roswell Park Memorial 
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Institute medium (RPMI) supplemented with 10% fetal bovine serum and 1% penicillin 
streptomycin procured from Gibco BRL (Life Technologies, UK). 
2.2 Synthesis of TPGS-Gemcitabine prodrug 
The TPGS-Gem prodrug was synthesized in a two-step process. The first step involves 
functionalization of TPGS with the terminal free carboxyl group by esterification through 
succinic anhydride (SA) and a catalytic amount of dimethylamino pyridine (DMAP) 
34
. 
Subsequently, the second step involves the amidation of an amino group on gemcitabine with 
functionalised carboxyl group of TPGS. The schematic illustration of the synthetic route is 
shown in Figure-1. In brief, TPGS (1 equivalent), succinic anhydride (2 equivalent), and 
dimethylamino pyridine (1 equivalent) were dissolved in dry dichloromethane (DCM) and 
reacted under a nitrogen atmosphere for 24 h at room temperature (RT). The reaction mixture 
was filtered and precipitated in cold diethyl ether and dried under vacuum. The precipitated 
product was taken up in DCM and dialyzed (Pur-A-Lyzer dialysis kit, MWCO 1000, Sigma) 
against 50:50 mixture of ethanol: water for 72 h to remove excess amount of DMAP and SA. 
The TPGS-SA was dried under vacuum and stored at -20 
0
C until further use. 
 The conjugation of the amino group of gemcitabine and carboxyl group of TPGS-SA was 
achieved by classical carbodiimide coupling reaction. In brief, TPGS-SA (1 equivalent), di-cyclo 
hexyl carbodiimide (DCC, 2 equivalent), N-hydroxy-succinimide (NHS, 2 equivalent) was 
dissolved in anhydrous DMSO and reacted for 24 h at RT under nitrogen conditions. The 
reaction was filtered using 0.45 µm syringe filter, to remove the by-product N, N-
dicyclohexylurea. The filtrate was mixed with a solution containing gemcitabine (2 equivalent of 
TPGS-SA) and triethylamine (2 equivalent) in DMSO and kept under stirring for further 24 h in 
a nitrogen environment at RT. The reaction mixture was dialysed (Pur-A-Lyzer dialysis kit, 
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MWCO 1000, Sigma) against DMSO to remove unreacted gemcitabine for 24 h. Afterward, the 
dialyzing media was replaced by water to remove DMSO and reaction mixture was freeze-dried 
to obtain TPGS-Gem prodrug.  
2.3 Characterization of TPGS-Gemcitabine prodrug 
The conjugation between TPGS and gemcitabine was validated by different analytical methods 
including Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance 
(NMR) spectroscopy and MALDI-TOF spectroscopy. The FT-IR spectra for TPGS, TPGS-SA 
gemcitabine and TPGS-Gem prodrug were recorded from Perkin Elmer, FT-IR spectrometer. 
Neat samples were analyzed to detect IR bands over a range 3500-800 cm
-1
. 
1
H-NMR spectrum 
of native gemcitabine, TPGS, TPGS-SA, and TPGS-Gem, were acquired on a Bruker DRX 300 
MHz NMR spectrometer. Tetramethylsilane was used as an internal standard. A mass spectrum 
of native TPGS, TPGS-SA, and TPGS-Gem were obtained by MALDI-TOF (Applied 
Biosystems/AB Sciex) equipped with ND-YAG diode pump laser (355 nm/200 Hz). The 
instrument was run in a positive ion reflection mode using CHCA (a-cyano-p-hydroxycinnamic 
acid) as a matrix.  Respective peptide standards were used to calibrate the mass range. The 
spectra were recorded in the range of 800 to 2400 Da. 
2.4 RP-HPLC analysis 
The content of gemcitabine conjugated to TPGS-gemcitabine prodrug was determined using RP-
HPLC method 
35
. Alkaline hydrolysis was performed in KOH 0.1 N to separate the native 
gemcitabine from TPGS moiety. In brief, 1mg/ml concentration of TPGS-Gem was incubated 
with 0.1 N of KOH at 40 
0
C for 1 h. Samples were appropriately diluted with acetonitrile and the 
amount of gemcitabine quantified by HPLC (Perkin Elmer) analysis. The samples were analyzed 
using HPLC equipped with RP-18 column (E-Merck, 5µm, 4.0 x 250mm) with PDA detector. 
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Acetonitrile and 0.02 M ammonium acetate buffer (1:1) was used as mobile phase at flow rate 
0.5 ml/min. The detection wavelength (λmax) for gemcitabine was 268 nm and retention time of 
gemcitabine was found to be 4.08 min. 
2.5 Preparation of TPGS-Gemcitabine prodrug micelles 
TPGS-Gem prodrug micelle was prepared by a simple solvent evaporation method with minor 
modifications 
36
. Briefly, 30 mg of TPGS-Gem prodrug was solubilized in 1.5 ml of ethanol and 
added drop-wise to 15 ml of ultra-purified water under stirring. The solution was stirred gently 
on magnetic stirrer to evaporate organic solvent. The resultant mixture was filtered by 0.45 µm 
poly(ethersulfone) syringe filter. For storage, the micelles were freeze dried and kept refrigerated 
until further use. 
2.6 Micelles characterization  
The average particle size, size distribution, polydispersity index (PDI) and surface charge of 
prepared micelles were determined through dynamic light scattering (DLS) (Zetasizer, ZS-Nano, 
Malvern, UK). The particle size measurement was performed using disposable poly(styrene) 
cells, the micelle solution was incubated at various temperatures (25-40 
0
C) for 10 min. to attain 
the equilibrium. The zeta potential of micelles solution was measured using plain folded zeta 
cells, at 25 
0
C on fixed scattered light at an angle 90 
0
. All measurements were performed in 
triplicate. The morphological investigation of prepared micelles was performed using JEOL 
JEM-1230 transmission electron microscope (JEOL, Japan). A drop of the micellar formulation 
was carefully placed on the formvar-coated copper grid (200 mesh) and then dried at room 
temperature overnight before observation on the microscope. 
2.7 Critical micelle concentration using UV hydrophobic probes 
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The critical micelle concentration (CMC) of TPGS-Gem prodrug was investigated by UV 
hydrophobic probe, methyl orange, as described by Uchegbu et al.
37
. In brief, a methyl orange 
(25 µM) stock solution was prepared using sodium tetraborate buffer (0.02 M, pH 9.4) in 
deionised water. A solution of 10 mg/ml concentration of TPGS-Gem prodrug was prepared in 
methyl orange solution. Various concentration (0.015 mg/ml-2.5 mg/ml) of TPGS-Gem was 
prepared by serial dilution of prodrug solution using methyl orange stock as diluent. Each 
concentration was scanned in the UV-visible spectrophotometer (UV-2600, Shimadzu) between 
350-600 nm and maximum absorbance (λ max) was registered. The λ max of aqueous methyl 
orange stock solution was recorded as control (i.e. 0 mg/ml surfactant). A graph was plotted 
between λmax vs. surfactant concentration. The CMC is identified as the inflection point 
(hypsochromic shift) at the beginning of the curve on the graph plotted against λmax vs. TPGS-
Gem concentration. 
2.8 In vitro drug release 
In vitro drug release study of TPGS-Gem micelles was performed in buffer solution with pH 7.4 
at various temperatures i.e. 30, 37 and 40 
0
C. In brief, 3 ml of TPGS-Gem micelle solution was 
placed in a dialysis bag (MWCO 1000) and immersed with 20 ml of buffer solutions in a shaker 
incubator at temperature 30, 37 and 40 
0
C. At scheduled time intervals, 100 µl of the sample was 
collected from buffer solution and replaced with the same amount of fresh buffer of the same 
temperature. The collected samples were analyzed by validated RP-HPLC method reported 
above. Experiments were performed in triplicates for up to one week.  
2.9 Stability studies with cytidine deaminase 
The TPGS-Gem micelles and native gemcitabine were exposed to cytidine deaminase, in order to 
evaluate the metabolism triggered by the enzyme. Briefly, 0.4 mM concentration of TPGS-Gem 
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micelles and gemcitabine were prepared in 0.1 M Tris buffer (pH 7.5) with respect to 
gemcitabine concentration. The reactions were initiated by addition of 10 µl of recombinant 
human cytidine deaminase, dissolved 20 mM Tris-buffer, 2 mM EDTA and 40% glycerol in 1 ml 
of each solution. At various time points, 60µl of aliquots were collected mixed with 30 µl of 
acetonitrile to terminate the enzyme activities. The solvent of the reaction mixture was 
evaporated using freeze drying. The dried sample was reconstituted in 100 µl of water and 
analyzed by LC-MS/MS using the method described in our previous report 
17
. 
2.10 Cell culture methods 
BxPC-3 cells were cultured using RPMI medium supplemented with 10% fetal bovine serum 
(FBS) and 1% antibiotic (streptomycin and penicillin) solution in 50 ml cell culture flask. Cells 
were cultivated in a humidified incubator with 5% carbon dioxide at 37 
0
C. After 90% 
confluence level reached, cells were routinely trypsinised and subcultured. 
2.11 In vitro cytotoxicity 
For evaluation of the cytotoxic potential of TPGS-Gem micelles, MTT assay was performed in 
comparison with gemcitabine and placebo TPGS micelles (i.e. TPGS micelles with no drug 
conjugated, in equivalent weight as in TPGS-Gem micelles) at incubation time 24 h, 48 h, and 72 
h. BxPC-3 cells were seeded for 24 h in 96 well flat bottom plates (Corning, USA) at a density of 
15x10
3
 cells/well in RPMI medium. Various concentrations of test samples were added to the 
cells and incubated for predetermined time intervals. After completion of the incubation period, 
the medium was replaced with 100 µl of MTT dye to each well at 0.5 mg/ml concentration and 
incubated for 4 h. The degree of cell viability is expressed by translation of MTT into purple 
formazan crystals by metabolically viable cells. The produced formazan crystals were dissolved 
using 100 µl of DMSO and optical density of wells was measured at wavelength 570 nm 
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spectrophotometrically (BioTek, Synergy HT). The nonlinear regression analysis was performed 
to determine a concentration caused a 50% inhibition in the control growth rate (IC50) using 
Graph Pad software. 
2.12 Nucleoside transporter inhibition 
Gemcitabine typically enters across the cellular membrane through nucleoside transporter (hENT 
and/or hCNT)
 38
. Since one or more of these nucleoside transporters are essential for gemcitabine 
to enter the cell, we performed a nucleoside transporter inhibition assay, to investigate whether 
TPGS-Gem micelles also dependent on nucleoside transporter. The MTT assay was performed 
as mentioned above with minor changes. BxPC-3 cell suspension was seeded in 96 well flat 
bottom plates and incubated for 24 h. A 10 µM concentration of dipyridamole (a nucleoside 
transporter inhibitor) was incubated with cells prior to sample addition to inhibiting the hENT-1 
transporter. The IC50 values were calculated to determine the effect of inhibition of nucleoside 
transporters.  
2.13 Cellular uptake 
A cellular uptake study was performed to demonstrate the internalization of TPGS-Gem micelles 
in the presence and absence of nucleoside transporter inhibitor, dipyridamole. Coumarin-6 
loaded TPGS-Gem micelles was prepared by same method as described for TPGS-Gem micelles, 
except that coumarin-6 was added in first step with the prodrug in ethanol. BxPC-3 cells were 
seeded onto a borosilicate glass cover slip in six well plates for 24 h. Then the media of three 
wells was replaced with a 10 µM concentration of dipyridamole to inhibit the nucleoside 
transporters, 30 min. before the addition of test samples. Afterwards the media of all six wells 
was substituted with 0.125 mg/ml of coumarin-6 loaded TPGS-Gem micelles and incubated for 4 
h at 37 
0
C in CO2 incubator. After completion of incubation time the cells were washed twice by 
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PBS (pH 7.4) and fixed with 70% ethanol and the nuclei was counter stained by DAPI (4-6 
diamidino-2phenyl indole). Then the cells were observed under fluorescence cell imaging station 
(EVOS FLoid). 
2.14 AFM topography 
The effect of morphological changes was assessed after treatment with TPGS-Gem micelles, 
gemcitabine, and native TPGS using atomic force microscope after 24 h of incubation. BxPC-3 
cells were seeded in 6 well plates over coverslips. Cells were incubated in a humidified incubator 
at 37 
0
C and 5% CO2 atmosphere. After 24 h, the media was replaced with a 10 µM. the 
concentration of gemcitabine and TPGS-Gem micelles dissolved in media and incubated for 24 
h. The control cells were treated with media only. Afterward, the media was removed and cells 
were washed abundantly with PBS and fixed using 2.5% solution of glutaraldehyde prepared in 
PBS for 10 min. After fixation cells were again washed 5-6 times with PBS and mounted on a 
glass slide. Cell topography was imaged using a Bruker Bio Catalyst atomic force microscope 
(Bruker, Germany) using Peak Force Tapping Mode and a Scan Asyst in air cantilever. 
3. Results and Discussion 
The TPGS-Gem micelle was prepared after synthesis of TPGS-Gem prodrug. The gemcitabine 
was conjugated to TPGS through a succinate linker as a two-step process: (I) modification of end 
group of TPGS to a carboxylic group using succinic anhydride and (II) coupling of activated 
ester form of succinic acid-modified TPGS to the amino group of gemcitabine using classical 
carbodiimide chemistry, as shown in Figure-1. All the reactions performed to synthesize TPGS-
Gem prodrug were characterized by different analytical techniques including FT-IR, 
1
H-NMR, 
and MALDI-TOF. 
3.1 Characterization of TPGS-Gem prodrug 
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3.1.1 Fourier transform infrared spectra 
The FT-IR spectra of native TPGS (Figure-2) showed a characteristic band on 1736 cm
-1
 is 
attributed to the carbonyl group present in the TPGS. In the FT-IR spectra of TPGS-SA the 
strong absorption of carbonyl band at 1732 cm
-1
 was observed, which confirmed the formation of 
TPGS-SA, these findings are in accordance with previous reports 
34, 46
. Moreover, in the FT-IR 
spectra of gemcitabine, the band found at 1674 cm
-1 
and 1662 cm
-1 
attributed as a characteristic 
amine bending vibrations. In contrast, the FT-IR spectra of TPGS-Gem prodrug showed the 
characteristic carbonyl band at 1734 cm
-1
, in addition, bands at 1654 cm
-1
 and 1560 cm
-1
 
represents amide I (C=O, stretching) and amide II (N-H bending), respectively, confirmed the 
formation of amide bond between terminal carboxyl group of TPGS and primary amino group of 
gemcitabine 
17
. 
3.1.2 Nuclear magnetic resonance spectroscopy    
The structure of TPGS-Gem prodrug was also corroborated by 
1
H NMR spectra (Figure-3). In 
the 
1
H NMR spectrum of TPGS, the signals of ethylene protons of PEG chain, present in TPGS 
were observed at δ 3.5-3.6. The signals registered in the aliphatic region (δ1-3) of spectra 
attributed to the various protons of Vitamin E-tail. 
1
H NMR spectra of TPGS-SA showed similar 
signals as observed in the spectra of TPGS except succinyl methylene (-CH2) protons at δ 2.6-
2.7, confirmed the reaction between TPGS and succinic anhydride
34
. In the 
1
H NMR spectrum of 
gemcitabine, peaks at δ 8.2 correspond to the protons of a 4-amino group of gemcitabine. Other 
characteristic signals of 5’ and 3’OH of gemcitabine was registered at δ 6.08 and 6.28 
respectively 
20
. The 
1
H NMR spectra of TPGS-Gem prodrug showed the characteristic ethylene 
protons of PEG chain at δ 3.5 with various protons of vitamin E-tail. However, the peak of the 
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amino group of gemcitabine was shifted from δ 8.2 to δ 11.2 suggested the formation of an 
amide bond between gemcitabine and TPGS 
20, 40
.  
3.1.3 MALDI-TOF mass spectroscopy 
The MALDI-TOF spectra of TPGS, TPGS-SA and TPGS-Gem was investigated to assign the 
formula of various oligomeric compositions with different adduct and charge states (Figure-4). 
The molecular formula of TPGS forming potassium adduct was validated as C33H54O5-
(CH2CH2O)n + K. In the MALDI spectrum of TPGS-SA, a marked 100 Da increment in the 
mass of various oligomers was observed, which is equal to the mass of succinic anhydride, 
suggesting the reaction between TPGS and succinic anhydride. An expected empirical formula 
for various oligomers of TPGS-SA forming potassium adduct could be [C33H53O5-(CH2CH2O)n]-
CO-C2H4-COOH+K. Moreover, the MALDI spectra of TPGS-Gem prodrug showed an 
increment of 245 Da in oligomeric clusters as compared to the oligomers of TPGS-SA, which is 
similar to the increment of mass if gemcitabine conjugated to TPGS-SA via an amide bond. 
However, there was no adduct (including K, Na) was seen in the oligomeric clusters of TPGS-
Gem spectra. Furthermore, in the spectra of TPGS and TPGS-SA the oligomers presents in 
different charge state. 
For instance, the reaction between TPGS oligomer with n-value 20, [C33H54O5- 
(CH2CH2O)20, 1411 Da; or m/z 1450 in the potassium salt form] occurs with succinic acid would 
lead to the species at m/z 1511 (or m/z 1550 in the form of potassium salt) and further reaction 
with gemcitabine would lead to the species at 1757 (with no adduct formation). By comparing 
the spectra of TPGS, TPGS-SA and TPGS-Gem an increment of the abundance of the ion at 
1550 in TPGS-SA and 1757 in the spectra of TPGS-Gem is clearly visible, confirmed the 
transformation of the terminal hydroxyl group to the carboxyl group at TPGS terminal end after I 
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step of reaction and formation of an amide bond between TPGS-SA and gemcitabine after II 
step. The similar behavior was noticed for all other oligomeric species. The concise table of 
proposed formulas of oligomeric compositions of TPGS-Gem prodrug and intermediates is given 
in supporting information. The conjugation of gemcitabine to TPGS is an important 
consideration since gemcitabine as a hydrophilic drug have very low encapsulation efficiency in 
polymeric nanoparticles. TPGS-Gem micelles could be used as a new strategy to deliver 
hydrophilic drug if the loading efficiency is high. The amount of drug conjugated to TPGS was 
calculated to be 36.3 ± 2.5 µg/mg of TPGS-Gem prodrug, which is higher than our previous 
investigation (i.e. 0.124 mol of gemcitabine/mol of PLGA) in which an antiproliferative activity 
of PLGA-Gemcitabine polymeric conjugate was demonstrated 
17
.  
3.1.4 Micelle generation and characterization 
The TPGS-Gem micelles were generated by simple solvent evaporation method as described 
above. The amphiphilic TPGS-Gem prodrug generates micelles by self-assembly in aqueous 
solution. After evaporation of the solvent, the generated micelles were characterised using 
various physicochemical parameters. 
3.1.5 Particle size, zeta-potential and morphological analysis 
The average particle diameter of TPGS-Gem prodrug was investigated upon nano-aggregation 
into micelles at different temperatures (25, 30, 35, 40 
0
C). No significant alteration was observed 
in the hydrodynamic diameter at selected temperatures, suggested that temperature does not 
influence the average particle size of micelles. An average particle size at 25 
0
C was measured as 
15.09 ± 0.7 nm (Figure-5A) with polydispersity index, 0.078 ± 0.025. Further at higher 
temperature the change in size of TPGS-Gem micelles has been observed to be negligible and 
the average hydrodynamic was registered as 15.67±0.16, 15.38±0.34, 15.94±0.59 and PDI 
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0.19±0.02, 0.115±0.037, 0.153±0.032 respectively, at temperature 30 
0
C, 35 
0
C and 40 
0
C.  The 
zeta potential of the micelles was evaluated as -9.3 ± 0.61 mV (Figure-5B). Particle size and zeta 
potential are the key factors for achieving the therapeutic efficacy of nanomedicines and micelles 
typically between 10 nm-100 nm are known to be favorable for drug delivery in cancer therapy 
41
. Particles smaller than 10 nm in size will be rapidly abolished through renal clearance 
(threshold < 6 nm) and greater than 100 nm, have a probability to uptake by reticuloendothelial 
system (RES) 
42
. Moreover, either neutral or anionic surface charge is considered beneficial for 
nanocarriers for successful evasion of renal elimination could result long circulatory action in 
vivo 
43
. The transmission electron microscopy (TEM) was used to determine the morphology of 
TPGS-Gem micelles; from which it can be seen that micelles have generally spherical shape 
(Figure 5C), however, a slightly bigger than the particle size was observed with DLS. The 
difference in the size obtained by two techniques could be due to the melting property of TPGS 
(melting point-38 
0
C).  The micelles experience a certain extent of melting and expansion in size 
due to a high energy electron beam in TEM which makes them appear bigger in the images 
captured by TEM 
44
. 
3.1.6 Critical micelle concentration  
The CMC value of TPGS-Gem prodrug and native TPGS was investigated using methyl orange 
as a hydrophobic probe in aqueous solution by monitoring the hypsochromic shift in methyl 
orange UV spectra (Figure 5D). Methyl orange has λmax at 464 nm in the presence of UV light. 
When a surfactant was diluted in methyl orange solution, it favours the hydrophobic core formed 
from the micelles of the amphiphilic polymers and a hypsochromic shift was experienced at 
critical micelle concentration value on UV spectra of amphiphilic polymer or surfactant 
45
. The 
effect of concentration of TPGS-Gem prodrug on the peak absorption of methyl orange at λmax 
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464 nm is given in the Figure-5D. The native TPGS exhibited the CMC value at 0.2 mg/ml 
(0.02%) 
46, 47
 and it was observed that the CMC value of TPGS-Gem prodrug was 0.15 mg/ml 
(0.015%). The lower CMC value of micelles indicated high stability, which prevents its 
dissociation into unimers upon dilution with large blood volume. 
3.1.7 In-vitro drug release 
The rate of gemcitabine release from TPGS-Gem micelles was evaluated in PBS buffer (pH 7.4) 
at various temperatures (30, 37 and 40 
0
C).  As illustrated in Figure-6 the release of gemcitabine 
from prodrug micelles showed significantly slower release at 30 
0
C than that at 37 and 40 
0
C. 
However, a lower increment of drug release at temperature 40 
0
C was observed than that of drug 
release at 37 
0
C. Under all temperatures the release of gemcitabine began as an initial slow 
release (2.4% at 30 
0
C, 8.5% at 37 
0
C and 10% at 40 
0
C in 1 h) followed by a continued sustained 
release and exhibited a similar release pattern at all the temperatures initially. The release of 
gemcitabine after 48 h was 38 % at 30 
0
C, 59 % at 37 
0
C and 64 % at 40 
0
C and a sustained 
released was observed subsequently. The accumulative release at one week was measured as 
58% at 30 
0
C, 89% at 37 
0
C 59% and 95% at 
0
C. The drug release study demonstrated that 
TPGS-Gem micelles were able to sustain gemcitabine release at selected temperatures. 
3.2 Stability studies with cytidine deaminase 
After intravenous administration, gemcitabine undergoes extensive metabolism to its inactive 
form, either intracellular or extracellular, due to the activity of CDA
10
. The stability of 
gemcitabine in the micellar formulation was investigated after incubation with crude CDA in 
comparison with parent gemcitabine. The concentration of drug was quantified at various time 
intervals using LC-MS/MS. As a function of incubation time with cytidine deaminase, the 
concentration of gemcitabine is shown in Figure-7. The disappearance in the native gemcitabine 
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was observed time-dependently and only around 11% of gemcitabine was detected after 30 min 
of incubation. Whereas, highly significant resistant was observed in the gemcitabine micellar 
formulation with more than 90% of gemcitabine can be detected after 30 min of incubation with 
crude CDA. This modest degradation of gemcitabine in TPGS-Gem micelles demonstrated the 
stability of formulation against CDA. These results are in accordance with previous reports, 
suggested that substitution of a 4-(N) amino group of gemcitabine prevents enzymatic 
degradation 
20, 48
. 
3.3 In vitro cytotoxicity  
The in vitro antiproliferative activity was performed by standard MTT assay after incubation of 
TPGS-Gem micelles, gemcitabine and placebo TPGS micelles with BxPC-3 cells as a model 
pancreatic cancer cell line at different incubation points i.e. 24 h, 48 h, and 72 h (Figure 8A, B, C 
respectively). Results suggested that the various test samples exhibited dose and time dependent 
cytotoxicity against BxPC-3 cells. It is noteworthy that placebo TPGS micelles also showed 
significant antiproliferative activity. The TPGS-Gem micelles and placebo TPGS micelles 
showed highly significant growth inhibition of BxPC-3 cells after 24 h as compared to 
gemcitabine. The IC50 value of native gemcitabine was evaluated as 165±8.65 µM at 24 h of 
incubation time while the IC50 value of TPGS-Gem micelles was 6.13±0.35 µM, and the IC50 
value of the equivalent amount of placebo TPGS micelles was found to be 9.09±0.7 µM. Further, 
after 48 h of incubation with samples, a similar trend was observed and TPGS-Gem micelles 
showed a significant higher cytotoxicity as compared to gemcitabine, however, the IC50 value of 
gemcitabine decreased massively to 2.4±0.23 µM, and the IC50 value of TPGS-Gem micelles and 
placebo TPGS micelles was demonstrated as 1.6±0.26 µM, 3.1±0.28 µM, respectively. A further 
extend in the incubation time to 72 h, continued to decrease the drug concentration necessary to 
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50% of growth inhibition. The IC50 values were decreased to 0.27±0.1 µM, 0.6±0.22 µM, and 
1.76±0.22 µM for gemcitabine, TPGS-Gem micelles, and placebo TPGS micelles respectively. 
However, there a comparable difference was showed in the IC50 value of gemcitabine and TPGS-
Gem micelles after 72 h of incubation (Figure-8D). The enhanced cytotoxic efficacy of 
gemcitabine could be due to the intrinsic anticancer efficacy of TPGS and/or stability of 
gemcitabine in micellar formulation against cytidine deaminase, which can convert the 
monophosphorylated form of gemcitabine to an inactive metabolite. 
3.4 Nucleoside transporter inhibition 
Due to the highly hydrophilic character of gemcitabine, it relies on the nucleoside transporter to 
cross the cellular lipid bilayer and display its antiproliferative activity. A resistance mechanism 
of gemcitabine includes deficiency of nucleoside transporters, causes decrease in the transport 
activity of drug into the cell 
49
.  Therefore, to assess the dependency of TPGS-Gem micelles on 
nucleoside transporters like gemcitabine, a nucleoside transporter inhibition assay was 
performed. During MTT assay, the cells were treated with dipyridamole, to block the nucleoside 
transporter, prior to addition of various concentration of TPGS-Gem micelles and gemcitabine. 
The IC50 values were determined against BxPC-3, pancreatic cancer cells after 48 h of incubation 
(Table-1). The IC50 value of native gemcitabine obtained after treatment with dipyridamole was 
11 µM, which is 5-fold higher than the IC50 value obtained with the cell not treated with 
dipyridamole. However, when TPGS-Gem micelles were treated with cells pre-incubated with 
dipyridamole, there was no significant change was observed in the IC50 value. These results 
reflect that TPGS-Gem micelles were not dependent on nucleoside transporter to cross the 
cellular lipid bilayer. 
3.5 Cellular uptake 
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The qualitative uptake of coumrin-6 loaded TPGS-Gem micelles in BxPC-3 cells was 
determined in the presence and absence of dipyridamole by measurement of fluorescence. 
Coumarin-6 was used as a fluorescent marker to identify the uptake of micelles in BxPC-3 cells. 
Figure-9 shows the uptake of TPGS-Gem micelles after 4 h of incubation with BxPC-3 cells, the 
green fluorescence was due to the coumarin-6 loaded micelles internalized by the cells. In order 
to confirm that fluorescence was present inside the cells, nucleus was counter stained with a 
DAPI, a blue fluorescent dye. The green fluorescence adjacent to the nucleus confirming the 
micelles were within the cells instead of attached to the cell surface. Furthermore, nearly all cells 
either in presence (Figure-9A) and absence (Figure-9D) of nucleoside transporter inhibitor were 
stained with green fluorescence suggesting that there was no significant difference in the uptake 
of micelles, suggesting that in the micellar formulation gemcitabine does not dependent on 
nucleoside transporters for internalization in the cells. These results can be correlated with the 
insignificant change in the IC50 values obtained after inhibition of nucleoside transporters by 
dipyridamole.  
3.5 AFM topography 
To study the morphological changes in BxPC-3 cells after treatment with TPGS-Gem micelles 
and native gemcitabine, the cells were observed under atomic force microscope (AFM). The 
control cells were treated with media only. It was observed that the control cell had a smooth 
well-defined morphology and showed an epithelial cell shape in general (Figure-10A). The AFM 
image of cell treated with native gemcitabine showed a smooth surface, however, marked 
specific degenerative alteration in the cell shape can be easily observed in the image (Figure-
10B). This could be correlated with the higher IC50 value of the gemcitabine after 24 h of 
incubation. Instead, in the AFM image of TPGS-Gem micelles treated cell, several pits on the 
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surface is clearly visible and the morphology of cell was also transformed (Figure-10C). The 
small pits on the cells attributed the morphological alteration in response to TPGS-Gem micelles 
50
.  The ability to visualize cellular state is advantageous in order to accurately demonstrate the 
effect of these formulations on the morphology and physiology. Although not qualitative these 
provide a good tool to compliment the cytotoxicity studies and provide insight into the likely fate 
of the cells. In this study the presence of pitting indicated that cellular morphology has been 
altered and perhaps cell membrane integrity has been compromised. This indicates that the cells 
are not residing in their ‘normal’ state. Hence, the observations of AFM topography suggested 
the enhanced efficacy of gemcitabine after formation of TPGS conjugated micelles. 
4. Conclusion 
In the present investigation, TPGS-Gem prodrug was synthesized and thoroughly characterised 
using analytical techniques. The micelles of TPGS-Gem prodrug were prepared and 
characterised for various physicochemical properties. The TPGS-Gem micelles were evaluated 
against the determinants, which hamper gemcitabine activity. The significant resistance of 
prepared micelles was observed against cytidine deaminase which may lead to long circulation 
half-life of gemcitabine. The prepared gemcitabine micelles exhibited enhanced anticancer 
activity in the selected cell lines as compared to free gemcitabine. It is remarkable that unlike 
gemcitabine, TPGS-Gem micelles were not relying on nucleoside transporter to cross the cellular 
lipid bilayer. Further, morphological studies suggested the potential anticancer activity of TPGS-
Gem micelles in vitro. Moreover, our findings provide a guideline for in vivo investigations to 
confirm the feasibility of micellar formulation for clinics. 
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Legends (Figures) 
Figure-1 A schematic representation of the reaction involved in the synthesis of Tocopherol 
polyethylene glycol succinate 1000 (TPGS)-gemcitabine prodrug. 
Figure-2 Stacked Fourier transform-infrared (FT-IR) spectra of TPGS, gemcitabine and 
TPGS-Gem prodrug scanned in the region of 3500 cm
-1
 to 800 cm
-1
. 
Figure-3 Stacked 
1
H-NMR (400 MHz) spectra of TPGS, TPGS-SA, gemcitabine, and 
TPGS-Gem micelles registered using trimethylsilane as an internal standard. 
Figure-4 Full mass overview spectra’s of TPGS (A), TPGS-SA (B) and TPGS-Gem 
prodrug (C) by MALDI-TOF. 
Figure-5 Representative particle size distribution (A) and zeta potential (B) of TPGS-Gem 
micelles measured by dynamic light scattering measurement at fixed 90
0
 angle at 
25 
0
C using disposable polystyrene cells and folded capillary cells respectively. 
(C) Transmission electron micrograph of TPGS-Gem micelles revealing size of 
micelles captured using a formvar-coated copper grid (D). Critical micelle 
concentration measurement of TPGS-Gem micelles using methyl orange as 
hydrophobic probe, inflexion point in the graph represents the CMC value.  
Figure-6 Metabolic stability of TPGS-Gem micelles in comparison to native gemcitabine. 
Micellar gemcitabine or free gemcitabine (0.4 mM) was incubated in a buffer (pH 
7.5) containing cytidine deaminase (10µl, specific activity 3.5unit/mg) at 37 °C. 
(*P < 0.05, n=3) 
Figure-7 Release profile of gemcitabine from TPGS-Gem micelles after incubation in PBS 
(pH 7.4) for one week, at various temperatures i.e. 30,  37 and 40 
0
C. The 
concentration of drug released at specific time point was analyzed validated HPLC 
method. (*P < 0.05, 30 
0
C vs 37 
0
C /40 
0
C, after Bonferroni correction, n=3) 
Figure-8 Percent of cell viability on different concentrations of gemcitabine, TPGS-Gem 
micelles and placebo TPGS micelles (i.e. TPGS with no drug conjugated, at 
equivalent weight as in TPGS-Gem micelles) against BxPC-3 cells at incubation 
time 24h (A), 48h (B) and 72h (C). The IC50 value obtained  cells after incubation 
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of samples at different time points (D). The results represent mean SD of three 
experiments. *P < 0.05 vs. Gemcitabine/ Placebo TPGS micelles 
Figure-9 Demonstration of cellular uptake of TPGS-Gem micelles using fluorescence microscopy 
in BxPC-3 cell lines in presence (A-C) and absence (D-F) of nucleoside transporter, 
dipyridamole. Micelles up-taken by cells showing green fluorescence and nuclei stained 
by DAPI showing blue fluorescence. Images were captured using EVOS® Floid® cell 
imaging station. 
Figure-10 Effect of gemcitabine and TPGS-Gem micelles on the cellular morphology in 
human pancreatic cancer cell line (BxPC-3) by AFM topography. The cells were 
treated with a 10µM concentration of test sample with respect to drug 
concentration in 6 well plates for 24h and fixed by 2.5% of glutaraldehyde before 
images were captured under AFM. (A) non-treated control cell, (B) cell treated 
with gemcitabine and (C) cell treated with TPGS-Gem micelles (arrow showing 
the pits on the surface of cell) 
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Figure-1 
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              Figure-2 
 
  
Page 29 of 38 RSC Advances
R
S
C
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
2/
06
/2
01
6 
15
:0
9:
04
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C6RA09347G
30 
 
 
 
Figure-3 
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Figure-5 
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Figure-6 
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            Figure-7 
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Figure-8 
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Figure-9 
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Figure-10 
 
Table-1: Effect of nucleoside transporter inhibitor on antiproliferative activity of gemcitabine 
and TPGS-gem micelles against BxPC-3 cell lines following 48h of incubation. 
Sample BxPC-3 Cells 
IC50 (µM) Relative gemcitabine resistance 
Gemcitabine 2.4 - 
Gemcitabine + dipyridamole 11.9 5 
TPGS-Gem micelles 1.6 - 
TPGS-Gem micelles + dipyridamole 1.3 0.82 
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